ALK and non-small cell lung carcinoma: To our knowledge, PEMBROREAL is the first real-world study reported in literature that focused on the use of pembrolizumab as a first-line treatment of NSCLC combined with pemetrexed and platinum in patients without driver mutation of EGFR and ALK and PD-L1 expression < 50%.